{"id":80332,"date":"2026-05-07T00:05:13","date_gmt":"2026-05-07T00:05:13","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/"},"modified":"2026-05-07T00:05:13","modified_gmt":"2026-05-07T00:05:13","slug":"totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/","title":{"rendered":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026"},"content":{"rendered":"<div>\n<p align=\"center\"><em>TOS-358 is a covalent, pan-mutant,\u00a0<\/em><em>a<\/em><em>-selective PI3K inhibitor designed to address key limitations of existing PI3K<\/em><em>a<\/em><em> therapies which include limited mutation coverage and poor tolerability<\/em><\/p>\n<p align=\"center\"><em>First presentation of combination data demonstrates 100% disease control rate and 89% clinical benefit rate in women, including PAM-experienced patients, with median time on therapy exceeding 24 weeks<\/em><\/p>\n<p align=\"center\"><em>Poster presented May 7, at ESMO Breast Cancer Annual Congress 2026 in Berlin, Germany<\/em><\/p>\n<p>EMERYVILLE, Calif., May  06, 2026  (GLOBE NEWSWIRE) &#8212; Totus Medicines, a clinical-stage, precision medicines company leveraging AI-powered small molecule drug discovery to advance a differentiated pipeline of therapeutics against high-value, historically difficult-to-drug targets, today announced the presentation of interim Phase 1b clinical data from its ongoing study of TOS-358, a next-generation pan-mutant, covalent, alpha-selective PI3Ka inhibitor, in combination with Fulvestrant, in heavily pre-treated metastatic HR+\/HER2\u2212 breast cancer patients. The data were presented at the European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress, taking place in Berlin, Germany, May 5\u20138, 2026.<\/p>\n<p><strong>Presentation Details:<\/strong><\/p>\n<p>Conference: ESMO Breast Cancer 2026<\/p>\n<p>Session: Poster Presentation<\/p>\n<p>Abstract Number: 492P<\/p>\n<p>Date \/ Time: 13:15, Thursday, May 7, 2026<\/p>\n<p>\u201cThese initial combination data with TOS-358 and Fulvestrant are highly encouraging and reinforce our confidence in TOS-358\u2019s differentiated profile as a covalent, pan-mutant PI3Ka inhibitor,\u201d said Zelanna Goldberg, M.D., Chief Medical Officer of Totus Medicines. \u201cAchieving 100% disease control and an 89% clinical benefit rate in women, including patients with prior PI3K\/AKT\/mTOR pathway therapy, alongside a class-leading tolerability profile, underscores the potential of TOS-358 to address a critical unmet need in HR+\/HER2\u2212 metastatic breast cancer. The durability of responses, with more than 60% of patients remaining on therapy beyond 24 weeks, further validates our approach of near-total, sustained PI3Ka pathway suppression.\u201d<\/p>\n<p><strong>First Combination Data: TOS-358 + Fulvestrant Efficacy and Durability<\/strong><\/p>\n<p>The poster (Abstract 492P) presents the early clinical data from the doublet cohort of TOS-358-001, the ongoing open-label, global, multi-center Phase 1 study. Ten evaluable HR+\/HER2\u2212 breast cancer patients were treated with TOS-358 in combination with Fulvestrant (median 3.5 prior lines of therapy; range 1\u20135), with a data cutoff of March 31, 2026. Key efficacy and durability findings include:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;\">100% Disease Control Rate (DCR) in women treated with TOS-358 + Fulvestrant<\/li>\n<li style=\"margin-bottom:6pt;\">89% Clinical Benefit Rate (CBR) in women, including patients who had received prior PI3K\/AKT\/mTOR (PAM)-directed therapy and patients in the 4th line and beyond<\/li>\n<li style=\"margin-bottom:6pt;\">Responses continued to deepen over time, including conversions from stable disease (SD) to partial responses (PR), consistent with TOS-358\u2019s near-total inhibition of PI3Ka signaling<\/li>\n<li style=\"margin-bottom:6pt;\">60% of patients on TOS-358 + Fulvestrant remained on therapy beyond 24 weeks, with an additional 20% of patients ongoing at less than 24 weeks on trial; median time on therapy exceeds 24 weeks for the overall Phase 1 population<\/li>\n<li style=\"margin-bottom:6pt;\">A 72-year-old heavily pre-treated patient with an H1047K\/G106V dual PI3Ka mutation achieved a confirmed RECIST partial response of ~68%, with near complete PET-CT resolution of bone metastases<\/li>\n<\/ul>\n<p><strong>Class-Leading Safety and Tolerability<\/strong><\/p>\n<p>Across the overall TOS-358 safety population to date (N=56, including monotherapy and doublet patients), TOS-358 demonstrated a class-leading tolerability profile with an absence of toxicities that have limited other PI3Ka inhibitors:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;\">0% bone marrow toxicity<\/li>\n<li style=\"margin-bottom:6pt;\">0% hepatic toxicity<\/li>\n<li style=\"margin-bottom:6pt;\">0% renal toxicity<\/li>\n<li style=\"margin-bottom:6pt;\">0% ocular symptoms<\/li>\n<li style=\"margin-bottom:6pt;\">0% rash<\/li>\n<li style=\"margin-bottom:6pt;\">0% stomatitis\/mucositis<\/li>\n<li style=\"margin-bottom:6pt;\">0% grade 3 diarrhea<\/li>\n<li style=\"margin-bottom:6pt;\">Hyperglycemia was manageable: only 3.6% of patients (2\/56) required ongoing insulin, and all patients who received insulin were obese (BMI &gt;30)<\/li>\n<li style=\"margin-bottom:6pt;\">No treatment discontinuations due to intolerance to TOS-358<\/li>\n<\/ul>\n<p><strong>Maturing Overall Phase 1 Experience<\/strong><\/p>\n<p>The overall Phase 1 cohort currently demonstrates a 78% DCR and 57% CBR, with data continuing to mature. Among the overall population treated with TOS-358, median time on therapy now exceeds 24 weeks, with 50% of patients maintaining disease control beyond this landmark. The ongoing Phase 1b expansion cohort is currently enrolling across doublet (TOS-358 + Fulvestrant) and triplet (TOS-358 + Fulvestrant + CDK4\/6 inhibitor) arms.<\/p>\n<p><strong>TOS-358: A Differentiated Approach to PI3K<\/strong>a<strong> Inhibition<\/strong><\/p>\n<p>TOS-358 is the first and only clinical-stage covalent PI3Ka inhibitor. As a pan-mutant, a-selective oral small molecule, TOS-358 achieves &gt;95% continuous target engagement at clinically relevant doses through covalent binding to a cysteine residue equally accessible in helical, kinase-domain, and other mutants of PI3Ka while avoiding high plasma concentrations that can potentially lead to off-target effects. This broad mutant coverage &#8211; extending to acquired resistance mutations &#8211; differentiates TOS-358 from non-covalent and mutation-selective PI3Ka inhibitors currently approved or in development. The near-total, sustained suppression of oncogenic signaling enabled by this mechanism is reflected in the depth and durability of responses observed clinically, as well as the absence of many of the class-effect toxicities that have limited other agents.<\/p>\n<p>PI3Ka driver mutations are present in approximately 40% of ER-positive\/HER2-negative breast cancer, 50% of endometrial adenocarcinoma, and a meaningful subset of head and neck squamous cell carcinoma (HNSCC) patients. Totus Medicines is advancing TOS-358 as a potential best-in-class PI3Ka inhibitor across selected solid tumor indications. TOS-358-001 (EU CT 2023-505346-26-01; NCT#05683418) is an ongoing open-label, global, multi-center Phase 1 study evaluating the safety and efficacy of TOS-358 alone and in combination.<\/p>\n<p><strong>About Totus Medicines:<\/strong><\/p>\n<p>Totus Medicines is a clinical-stage, precision medicines company, discovering novel covalent small molecules against previously undrugged or difficult to drug targets, based on its proprietary AI-powered OmniDEL platform (DNA-encoded covalent library technology). The company&#8217;s lead program, TOS-358, the first and only covalent PI3Ka inhibitor in clinical development, has shown efficacy, response and long-term disease control with class-leading tolerability in breast, endometrial and head &amp; neck cancers. The company&#8217;s lead pre-clinical program is targeting IRF5, a key genetically validated but previously undrugged target across multiple I&amp;I indications. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=50cqD_YlNmCqS_gVHpFIOfEvl33pdcyuv7r2vkA-j5EMeaIMLfqWokzyL5evX4Fm2hq-OnA8j7rkF0wnuNuNV9oBq1BUMA4nowa35wtRwz0=\" rel=\"nofollow\" target=\"_blank\" title=\"www.totusmedicines.com\">www.totusmedicines.com<\/a><\/p>\n<p><strong>Investor and Media Contact<\/strong><\/p>\n<p>ir@totusmedicines.com<\/p>\n<p>www.totusmedicines.com<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjhmNmU4YTYtYzUzMC00MTEyLTkxZTUtMjhlOTkxMjgxMDgyLTUwMDEyNDQ0Mi0yMDI2LTA1LTA2LWVu\/tiny\/Totus-Medicines.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TOS-358 is a covalent, pan-mutant,\u00a0a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include limited mutation coverage and poor tolerability First presentation of combination data demonstrates 100% disease control rate and 89% clinical benefit rate in women, including PAM-experienced patients, with median time on therapy exceeding 24 weeks Poster presented May [&#8230;]\n","protected":false},"author":1,"featured_media":85254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-80332","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026\" \/>\n<meta property=\"og:description\" content=\"TOS-358 is a covalent, pan-mutant,\u00a0a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include limited m\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-07T00:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1075\" \/>\n\t<meta property=\"og:image:height\" content=\"716\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026\",\"datePublished\":\"2026-05-07T00:05:13+00:00\",\"dateModified\":\"2026-05-07T00:05:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\"},\"wordCount\":953,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\",\"name\":\"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-05-07T00:05:13+00:00\",\"dateModified\":\"2026-05-07T00:05:13+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/","og_locale":"en_US","og_type":"article","og_title":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026","og_description":"TOS-358 is a covalent, pan-mutant,\u00a0a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include limited m","og_url":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-05-07T00:05:13+00:00","og_image":[{"width":1075,"height":716,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/04\/sgb-media-kit-2026.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026","datePublished":"2026-05-07T00:05:13+00:00","dateModified":"2026-05-07T00:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/"},"wordCount":953,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/","url":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/","name":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-05-07T00:05:13+00:00","dateModified":"2026-05-07T00:05:13+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/totus-medicines-presents-early-phase-1b-clinical-data-demonstrating-100-disease-control-rate-and-class-leading-safety-for-tos-358-fulvestrant-doublet-therapy-in-hr-her2-breast-cancer-at-esmo-breas\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Totus Medicines Presents Early Phase 1b Clinical Data Demonstrating 100% Disease Control Rate and Class-Leading Safety for TOS-358 + Fulvestrant Doublet Therapy in HR+\/HER2- Breast Cancer at ESMO Breast Cancer Annual Congress 2026"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80332","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=80332"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/80332\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/85254"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=80332"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=80332"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=80332"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}